title: Long-term response to GH therapy in short children with a delayed infancy-childhood transition (DICT).
abstract: Transition of growth from infancy to childhood is associated with activation of the GH-IGF-I axis. Children with a delayed infancy-childhood transition (DICT) are short as adults. Thus, age at ICT may impact on growth response to GH. The objective was to investigate associations between growth response to GH treatment and ICT timing in children with idiopathic short stature (ISS) in a randomized, controlled, multicenter trial, TRN 88-080. A total of 147 prepubertal children (mean age, 11.5 ± 1.4 y) were randomized to receive GH 33 μg/kg/d (GH33, n = 43), GH 67 μg/kg/d (GH67, n = 61), or no treatment (n = 43). Data on growth to final height (FH) were analyzed after categorization into those with normal (n = 76) or delayed ICT (n = 71). Within the GH33 group, significant height gain at FH was only observed in children with a DICT (p < 0.001), with each month of delay corresponding to gain of 0.13 SD score (SDS). For the GH67 group, the timing of the onset of the ICT had no impact on growth response. In conclusion, ISS children with a DICT responded to standard GH dose (better responsiveness), whereas those with a normal ICT required higher doses to attain a significant height gain to FH.
authors.affiliation: Göteborg Pediatric Growth Research Center, The Sahlgrenska Academy at University of Gothenburg, SE-41685 Gothenburg, Sweden. kerstin.albertsson-wikland@pediat.gu.se
authors.forename: Kerstin
authors.initials: K
authors.lastname: Albertsson-Wikland
authors.forename: Berit
authors.initials: B
authors.lastname: Kriström
authors.forename: Björn
authors.initials: B
authors.lastname: Jonsson
authors.forename: Ze'ev
authors.initials: Z
authors.lastname: Hochberg
mesh_terms: D000328:Adult; D001827:Body Height / Q000187:drug effects*; D002648:Child; D006130:Growth Disorders / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I